HPLC method development and validation for the estimation of axitinibe in rabbit plasma

HPLC method development and validation for the estimation of axitinibe in rabbit plasma

ABSTRACT A rapid, sensitive, and accurate high performance liquid chromatography for the determination of axitinibe (AN) in rabbit plasma is developed using crizotinibe as an internal standard (IS). Axitinibe is a tyrosine kinase inhibitor, used in the treatment of advanced kidney cancer, which work...

Full description

Bibliographic Details
Main Authors:	Achanta Suneetha, Sharmila Donepudi
Format:	Article
Language:	English
Published:	Universidade de São Paulo 2017-10-01
Series:	Brazilian Journal of Pharmaceutical Sciences
Subjects:	High performance liquid chromatography/method validation Axitinibe/determination Axitinibe/ kidney cancer treatment Crizotinibe Rabbit plasma Tyrosine kinase inhibitor
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502017000300607&lng=en&tlng=en

Similar Items

The multikinase inhibitor axitinib in the treatment of advanced hepatocellular carcinoma: the current clinical applications and the molecular mechanisms
by: Hao Jiang, et al.
Published: (2023-05-01)

A case of hyperammonemia occurring during treatment of metastatic renal cell carcinoma with axitinib
by: Shoichi Kimura, et al.
Published: (2023-07-01)

Axitinib targets cardiac fibrosis in pressure overload-induced heart failure through VEGFA-KDR pathway
by: Tiantian Jiao, et al.
Published: (2023-11-01)

Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study
by: Alessandra Dicitore, et al.
Published: (2023-11-01)

Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma
by: Jindrich Kopecky, et al.
Published: (2018-11-01)

Photoswitchable Azo- and Diazocine-Functionalized Derivatives of the VEGFR-2 Inhibitor Axitinib
by: Linda Heintze, et al.
Published: (2020-11-01)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
by: Na Wei, et al.
Published: (2018-03-01)

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
by: Bellesoeur A, et al.
Published: (2017-09-01)

Intralesional Axitinib Injection Mitigates Hypertrophic Scar by Inhibiting Angiogenesis Pathway: A Preliminary Study in a Rabbit Ear Model
by: Liu C, et al.
Published: (2023-10-01)

Development and validation of a nomogram to evaluate the therapeutic effects of second-line axitinib in patients with metastatic renal cell carcinoma
by: Dengqiang Lin, et al.
Published: (2023-02-01)

Axitinib in Ponatinib-Resistant B-Cell Acute Lymphoblastic Leukemia Harboring a T315L Mutation
by: Valentina Giudice, et al.
Published: (2020-12-01)

Pembrolizumab in Combination with Axitinib as First-Line Treatment for Patients with Renal Cell Carcinoma (RCC): Evidence to Date
by: Chau V, et al.
Published: (2020-08-01)

Case report: Pembrolizumab plus Axitinib related hypothyroid myopathy in two kidney cancer patients
by: Andrea Boutros, et al.
Published: (2022-12-01)

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial
by: Masatoshi Kudo, et al.
Published: (2021-04-01)

Efficacy of combination therapy with pembrolizumab and axitinib for metastatic renal collecting duct cell carcinoma: A report on two cases
by: Shinji Tamada, et al.
Published: (2022-11-01)

Combination Therapy of Pembrolizumab plus Axitinib for a Patient on Hemodialysis with Metastatic Renal Cell Carcinoma: A Case Report
by: Yuki Katsumata, et al.
Published: (2021-10-01)

Outcomes of axitinib versus sunitinib as first‐line therapy to patients with metastatic renal cell carcinoma in the immune‐oncology era
by: Kazuyuki Numakura, et al.
Published: (2021-09-01)

Axitinibin sıçanlarda deneysel kornea neovascularizasyon modelinde inflamasyona etkisi
by: Necmiye CANACANKATAN, et al.
Published: (2018-12-01)

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC)
by: Ibon Gurruchaga Sotés, et al.
Published: (2021-06-01)

Axitinib and HDAC Inhibitors Interact to Kill Sarcoma Cells
by: Jane L. Roberts, et al.
Published: (2021-09-01)

Oxidative stress suppression contributes to antiseizure action of axitinib and rapamycin in pentylenetetrazol-induced kindling
by: O. B. Poshyvak, et al.
Published: (2021-04-01)

Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results
by: Gaetano Facchini, et al.
Published: (2019-08-01)

Losartan Alleviates the Side Effects and Maintains the Anticancer Activity of Axitinib
by: Ying Fu, et al.
Published: (2022-04-01)

Inhibition of Axitinib on Buspirone Metabolism in vitro and in vivo
by: Zhang BW, et al.
Published: (2022-06-01)

Bromide-assisted chemoselective Heck reaction of 3-bromoindazoles under high-speed ball-milling conditions: synthesis of axitinib
by: Jingbo Yu, et al.
Published: (2018-04-01)

Axitinib Rechallenge Restores the Anticancer Effect after Nivolumab: A Case Report
by: Yueh-Shih Chang, et al.
Published: (2023-07-01)

Theoretical investigation of fullerene (C60) as nano carrier for anti-cancer drug Axitinib
by: Saied Jamaladdin Emamjome Koohbanani, et al.
Published: (2024-03-01)

Axitinib in combination with radiotherapy for advanced hepatocellular carcinoma: a phase I clinical trial
by: Kai-Lin Yang, et al.
Published: (2021-01-01)

Combination of axitinib and dasatinib for anti-cancer activities in two prostate cancer cell lines
by: Nai-Xiong Peng, et al.
Published: (2015-12-01)

Case Study: A Japanese patient with metastatic renal cell carcinoma who achieved long‐term treatment‐free survival with pembrolizumab and axitinib in the KEYNOTE‐426 phase III trial of pembrolizumab and axitinib versus sunitinib
by: Koshiro Nishimoto, et al.
Published: (2022-05-01)

A case of an advanced renal collecting duct carcinoma in which initial therapeutic effect was achieved with pembrolizumab plus axitinib
by: Yuichiro Atagi, et al.
Published: (2024-01-01)

Low-dose axitinib rechallenge with positive outcomes in a patient with metastatic renal cell carcinoma refractory to interferon α, sunitinib, axitinib, and nivolumab therapies: a case report
by: Masaki Murata, et al.
Published: (2019-04-01)

Complete remission of brain metastases in renal cell carcinoma treated with axitinib after failure with nivolumab and ipilimumab treatment
by: Koichiro Takayama, et al.
Published: (2022-11-01)

Case report of a renal cell carcinoma patient with acute pancreatitis under both sunitinib and axitinib treatment
by: Utku Oflazoglu, et al.
Published: (2016-08-01)

A case of complete response to avelumab plus axitinib combination therapy for metastatic clear cell renal cell carcinoma in a kidney undergoing dialysis
by: Ei Shiomi, et al.
Published: (2024-03-01)

Avelumab plus axitinib therapy for renal cell carcinoma in a patient with pulmonary alveolar proteinosis: A case report
by: Nobuaki Shimizu, et al.
Published: (2021-11-01)

Epithelioid Angiomyolipoma with Tumor Thrombus into Inferior Vena Cava Presurgically Treated with Combination Therapy of Pembrolizumab and Axitinib: A Case Report
by: Kawasoe C, et al.
Published: (2023-10-01)

Avelumab plus axitinib for translocation renal cell carcinoma: A case series and literature review
by: Kenta Takahashi, et al.
Published: (2024-03-01)

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma
by: Tiako Meyo M, et al.
Published: (2022-07-01)

Axitinib after Sunitinib in metastatic renal cancer: preliminary results from Italian “Real-Word” SAX study
by: Carmine D'Aniello, et al.
Published: (2016-09-01)